Background. Gram-negative bacteremia (GNB) is a major cause of illness and death after hematopoietic stem cell transplantation (HSCT), and updated epidemiological investigation is advisable.
recipients, there is much interest in the identification of risk and prognostic factors, which may help determine tailored infection-control strategies [4] [5] [6] [7] [8] [9] [10] . Therefore, updated epidemiological investigation in this population is advisable.
To assess the incidence, risk and prognostic factors of pre-engraftment GNB in HSCT recipients, data from patients undergoing allogeneic HSCT (allo-HSCT) and autologous HSCT (auto-HSCT) during 2014 were prospectively registered. These data provide the basis for promoting direct efforts in risk stratification, prevention, and management of gram-negative bacterial infections in the HSCT population.
METHODS

Study Design
The Severe Infections by Gram-Negative Bacteria (SIGNB) study was sponsored by the Italian Stem cell Transplantation Network (Gruppo Italiano Trapianto di Midollo Osseo [GITMO] ) and the Italian Association of Clinical Microbiologists (Associazione Microbiologi Clinici Italiani [AMCLI] ). The SIGNB-GITMO-AMCLI study was a prospective epidemiological survey performed in 54 transplant centers in Italy between 1 January and 31 December 2014. Study start times could differ among centers, but all consecutive transplants were enrolled. The results of this study were reported according to the STROBE (STrengthening the Reporting of OBservational studies in Epidemiology) statement [11] . The study was approved by the ethical committee of each center, and informed consent was obtained from the patients.
Data Collection
Variables included patients characteristics, diagnosis and phase of the underlying disease, prior auto-HSCT or allo-HSCT, neutropenia within 30 days before HSCT, GNB documented within 3 months before HSCT, stem cell donor, stem cell source, pretransplant conditioning regimen, the use of "in vivo" T-cell depletion with antithymocyte globulin or cell manipulation ex vivo, antibacterial prophylaxis during the neutropenia period, colonization by resistant gram-negative bacteria at the pretransplant screening and during pre-engraftment, development of grade II-IV mucositis, duration of pre-engraftment neutropenia, development of grade II-IV acute graft-vs-host disease (GVHD) before engraftment, microbiologically documented bacterial and fungal infections, viral diseases and clinically documented infections before engraftment, survival at 4 months after HSCT, and cause of death. Information pertaining to the GNB included timing after HSCT and in vitro susceptibility.
Definition of Infection and Colonization
All cases of GNB with microorganism isolation from ≥1 blood culture were considered. For each isolate in vitro susceptibility data included sensitivity or nonsensitivity to the third-generation cephalosporin ceftazidime (ceph-S or ceph-NS) and sensitivity or nonsensitivity to carbapenems (carba-S or carba-NS) for enterobacteria (defined as a minimum inhibitory concentration >1 mg/L for imipenem, meropenem, and/or ertapenem) and multidrug resistance (MDR) for gram-negative nonfermenters (defined as resistance to ≥3 antimicrobial groups among piperacillin-tazobactam, ceftazidime, fluoroquinolones, aminoglycosides, and carbapenems).
The investigators were also asked whether their center routinely performed pre-and posttransplant surveillance of colonization by ceph-NS enterobacteria, carba-NS enterobacteria, and MDR nonfermenters, using culture of rectal/perianal swab samples, and reported the cases of colonization. Therefore, for the colonization analysis, we excluded patients who did not undergo such screening.
Analyses
The analyses were performed separately for auto-HSCT and allo-HSCT. The cumulative incidence of pre-engraftment GNB was calculated, accounting for the competing risks of infection-free death. Cumulative incidence of GNB was calculated for any type and status of the underlying disease, stem cell donor, stem cell source, pretransplant conditioning, history of GNB before transplant, antibacterial prophylaxis, and acute GVHD. Considering the different times of engraftment for the 2 transplant procedures, we calculated the cumulative incidence of GNB 20 days after auto-HSCT and 30 days after allo-HSCT. All factors were evaluated in multivariate models to control potential confounders using logistic regression methods.
Survival analyses were performed according to the above variables. Deaths were attributed to GNB in patients who failed to respond to therapy (ie, who had unstable disease or disease progression, according to the responsible physician judge) and in patients with a partial response to therapy who died because of an acute event involving any of the sites of infection and in the absence of other causes thought to have primarily contributed to death. The probability of 4-month survival after HSCT was calculated using Kaplan-Meier estimates, log-rank tests were applied for univariate analysis, and 2-sided P values ≤.05 were considered to represent statistical significance. Multivariate analyses were performed using a Cox proportional hazards regression model. In this model, variables related to GNB and acute GVHD were considered as time-dependent covariates in order to evaluate their effect only in the period after their onset. All significant variables in the univariate analysis were included in the multivariate analysis; final models were also evaluated with backward and stepwise function. Statistical analyses were performed using SAS software, version 9.4. SIGNB-GITMO-AMCLI is registered with Clinicaltrials.gov (NCT02088840).
RESULTS
Patient Characteristics
Overall, 1118 allo-HSCTs from 44 centers (median per center, 20; range, 2-105) and 1625 auto-HSCTs from 52 centers (23; 4-101) were included in the study. Demographics and patient characteristics at HSCT are shown in Table 1 . Most allo-HSCT and auto-HSCT recipients were affected by acute leukemia (65%) and multiple myeloma (52%), respectively. The vast majority of allo-HSCTs (74%) involved transplants from an HLA-mismatched related or unrelated donor.
Allo-Hematopoietic Stem Cell Transplantation
Pre-engraftment Infections and Details on Gram-Negative Bacteremia
The infections documented before engraftment are detailed in Table 2 . Overall, 149 GNBs were documented in 140 of 1118 allo-HSCTs (12.5%). The rate of GNBs by transplant center ranged from 0% to 39.1% (median, 11.7%). The median rate of GNB accounted for 11.1% in centers with lower transplant activity (≤20 HSCTs) and 13.2% in those with higher activity (>20 HSCTs) (P = .82). Escherichia coli was the most common gram-negative pathogen (77 cases; 51.7%), followed by Klebsiella pneumoniae (28 cases; 18.8%) and Pseudomonas aeruginosa (21 cases; 14.1%). The susceptibility pattern of the isolates is detailed in Table 3 .
Risk Factors for Gram-Negative Bacteremia in Allo-Hematopoietic Stem Cell Transplantation Recipients
The cumulative incidence of GNB 30 days after allo-HSCT was 17.3% (95% confidence interval [CI], 12.5%-22.7%) ( Figure 1A ). GNB-free pre-engraftment death occurred in 25 HSCT recipients (2.2%). The risk of GNB according to demographics, underlying disease, and transplant variables are detailed in Table 4 . By multivariate analysis, variables associated with increased risk of pre-engraftment GNB were acute leukemia, a transplant from an HLA-mismatched donor (related or unrelated) and from cord blood, older recipient age, and duration of severe neutropenia (polymorphonuclear leukocyte count <100/μL), and ex vivo graft manipulation was protective against GNB.
Risk of Gram-Negative Bacteremia According to Pretransplant Infection and Colonization
A pretransplant bloodstream infection by ≥1 gram-negative pathogen (88 isolates) was reported in 84 patients (7.5%) (ceph-S E. coli in 17, ceph-NS/carba-S E. coli in 17, ceph-S K. pneumoniae in 4, ceph-NS/carba-S K. pneumoniae in 9, carba-NS K. pneumoniae in 6, non-MDR P. aeruginosa in 11, MDR P. aeruginosa in 4, Enterobacter cloacae complex in 6, and other pathogens in 14) . An infection by the same species with the same susceptibility phenotype was documented in 16 of these 84 patients (19%) a median of 7 days (range, 1-25 days) after transplant (ceph-S 
cloacae complex in 1, and non-MDR P. aeruginosa in 3). A significantly increased risk of pre-engraftment GNB caused by the same species with the same susceptibility phenotype was documented in patients with a pretransplant GNB caused by ceph-NS/carba-S E. coli, carba-NS K. pneumoniae, or non-MDR P. aeruginosa. Pretransplant GNB caused by ceph-S E. coli did not represent a risk for a posttransplant infection by the same pathogen ( Figure 2 ). The rate of colonization by ceph-NS/carba-S E. coli, ceph-NS/ carba-S K. pneumoniae, carba-NS K. pneumoniae, and MDR P. aeruginosa and the rate of pre-engraftment infection according to colonization are detailed in Table 5 . Colonization by resistant gram-negative bacteria was always associated with a significantly increased risk of pre-engraftment infection by the same pathogen. In particular, a high probability of pre-engraftment infection by the same colonizing species 30 days after HSCT was observed for carba-NS K. pneumoniae (32.5% in colonized vs 0.1% in noncolonized; P < .001) and MDR P. aeruginosa (28.6% vs 0.6%; P < .001) ( Figure 3A ).
Survival
The overall survival 4 months after transplant was 86.3% (95% CI, 84.3%-88.4%). In multivariate analysis, acute leukemia, previous auto-HSCT, a disease not in complete remission at the time of HSCT, older age, prolonged pre-engraftment neutropenia, acute GVHD, and pre-engraftment GNB (hazard ratio, 2.13; 95% CI, 1.45-3.13; P <.001) were factors independently associated with increased mortality rate ( Table 6 ).
The mortality rate 30 days after the diagnosis of GNB was 17.9% (25 of 140 patients), and in 96% of patients (24 of 25) the infection was considered the primary cause of death. Of 46 patients who died before engraftment, the cause of death was a GNB in 18 (39.1%).
The probability of survival 4 months after allo-HSCT in 978 patients without any GNB was 88.3%, compared with 80.0% in 45 patients with ceph-S E. coli infection (P = .09), 86.7% in 30 with ceph-NS E. coli infection (P = .73), 40.0% in 15 with carba-NS K. pneumoniae infection (P < .001), 61.5% in 13 with non-MDR P. aeruginosa infection (P = .001) and 25% in 8 with MDR P. aeruginosa infection (P < .001) (Figure 4 ). 
Auto-Hematopoietic Stem Cell Transplantation
Pre-engraftment Infections and Details on Gram-Negative Bacteremia
The infections documented before engraftment are detailed in Table 2 . Overall, 151 GNBs were documented in 146 of 1625 auto-HSCTs (9.0%). The rate of GNB by transplant center ranged from 0% to 33.1% (median, 7.5%). The median rate of GNB accounted for 6.0% in centers with lower transplant activity (≤23 HSCTs) and 8.6% in those with higher activity (>23 HSCTs) (P = .93). E. coli was the most common gram-negative pathogen (92 cases; 60.9%), followed by K. pneumoniae (23 cases, 15.2%) and P. aeruginosa (13 cases; 8.6%). The susceptibility pattern of the isolates is detailed in Table 3 .
Risk Factors for Gram-Negative Bacteremia in Auto-Hematopoietic Stem Cell Transplantation Recipients
The cumulative incidence of GNB 20 days after transplant was 9.0% (95% CI, 8%-11%) ( Figure 1B ). GNB free pre-engraftment death occurred in 6 patients (0.4%). The risk of GNB according to demographics, underlying disease, and transplant variables are detailed in Table 4 . By multivariate analysis, variables associated with pre-engraftment GNB were a diagnosis of lymphoma, older recipient age, and no antibacterial prophylaxis.
Risk of Gram-Negative Bacteremia by Species According to Pretransplant Infection and Colonization
A pretransplant infection by a gram-negative pathogen was reported in 39 patients (2.4%) (ceph-S E. coli in 7, ceph-NS/carba-S E. coli in 5, ceph-S K. pneumoniae in 7, ceph-NS/carba-S K. pneumoniae in 2, carba-NS K. pneumoniae in 2, E. cloacae complex in 5, and other pathogens in 11). In only 3 patients was a posttransplant infection by the same pathogen documented (ceph-S E. coli, ceph-S K. pneumoniae, and carba-NS K. pneumoniae at 2, 7, and 7 days after transplant, respectively).
The rate of colonization by ceph-NS/carba-S E. coli, ceph-NS/ carba-S K. pneumoniae, carba-NS K. pneumoniae, and MDR P. aeruginosa and the rate of pre-engraftment infection according to colonization are detailed in Table 5 . A significant correlation between colonization and pre-engraftment infection by the same species 20 days after transplant was observed for ceph-NS/carba-S E. coli (10.5% in colonized vs 4.5% in noncolonized; P = .04), ceph-NS/carba-S K. pneumoniae (20.4% vs 0.3%; P < .001), and carba-NS K. pneumoniae (19.0% vs 0.01%; P < .001) ( Figure 3B ).
Survival
The overall survival 4 months after auto-HSCT was 97% (95% CI, 96.2%-97.9%). In multivariate analysis, a diagnosis of lymphoma, prolonged neutropenia during the month before auto-HSCT, a disease not in complete remission at the time of transplant, prolonged pre-engraftment neutropenia, and pre-engraftment GNB (hazard ratio, 2.43; 95% CI, 1.22-4.84; P = .01) were factors independently associated with increased mortality rates ( Table 6 ). The mortality rate 30 days after GNB diagnosis was 4.1% (6 of 146 patients), and in all 6 patients GNB was considered the primary cause of death. Of 11 patients who died before engraftment, the cause of death was a GNB in 4 (36.4%).
The probability of survival at 4 months after transplant in 1479 patients without any GNB was 97.5%, compared with 98.4% in 63 patients with ceph-S E. coli infection (P = .66), 93.1% in 29 with ceph-NS/carba-S E. coli infection (P = .13), 85.7% in 7 with ceph-S K. pneumoniae infection (P = .04), 90% in 10 with ceph-NS/carba-S K. pneumoniae infection (P = .14), 66.7% in 6 with carba-NS K. pneumoniae infection (P < .001), and 83.3% in 12 with non-MDR P. aeruginosa infection (P = .001). Abbreviations: Allo-HSCT, allogeneic hematopoietic stem cell transplantation; ATG, antithymocyte globulin; auto-HSCT, autologous HSCT; CI, confidence interval; CTC, common toxicity criteria; GVHD, graft-vs-host disease; HR, hazard ratio; NA, not applicable; PML, polymorphonuclear leukocyte.
DISCUSSION
The emergence of infections by gram-negative bacteria resistant to antibiotics has become a public health problem of major concern worldwide [12] [13] [14] . However, in HSCT populations, information regarding the current incidence and prognostic factors of gram-negative infections and their antibiotic resistance patterns is mainly limited to retrospective, single-center experiences [7, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . The GITMO-AMCLI-SIGNB survey, which included 64% of allo-HSCTs and 51% of auto-HSCTs performed in Italy in 2014, is a prospective study designed to critically assess the incidence and risk factors of GNB during the pre-engraftment period, and their impact on Figure 2 . Risk of pre-engraftment gram-negative bacteremia (GNB) recurrence after allogeneic hematopoietic stem cell transplantation (allo-HSCT) according to pretransplant GNB caused by the same species with the same susceptibility phenotype. (The risk was not calculated for other pathogens, for which the rates of pretransplant GNB were very low.) Abbreviations: Carba-NS, nonsensitive to carbapenems; carba-S, sensitive to carbapenems; ceph-NS, nonsensitive to the third-generation cephalosporin ceftazidime; ceph-S, sensitive to ceftazidime; E. coli, Escherichia coli; K. pneumoniae, Klebsiella pneumoniae; MDR, multidrug-resistant; P. aeruginosa, Pseudomonas aeruginosa. Abbreviations: Allo-HSCT and auto-HSCT, allogeneic and autologous hematopoietic stem cell transplantation; carba-R, resistant to carbapenems; carba-S, sensitive to carbapenems; ceph-R, resistant to the third-generation cephalosporin ceftazidime; GNB, gram-negative bacteremia; MDR, multidrug-resistant.
patient outcome. A valuable characteristic of this study was the availability of complete prospectively collected denominator data.
The overall pre-engraftment cumulative incidence of GNB was 17.3% at 30 days after allo-HSCT and 9% at 20 days after auto-HSCT. E. coli, K. pneumoniae, and P. aeruginosa were the Figure 3 . Risk of pre-engraftment gram-negative bacteremia (GNB) according to colonization by resistant GNB in allogeneic hematopoietic stem cell transplantation (allo-HSCT) (A) and autologous HSCT (auto-HSCT) (B) recipients. The risk was not calculated for other resistant pathogens, for which the rates of colonization were very low.) Abbreviations: Carba-NS, nonsensitive to carbapenems; carba-S, sensitive to carbapenems; ceph-NS, nonsensitive to the third-generation cephalosporin ceftazidime; E. coli, Escherichia coli; K. pneumoniae, Klebsiella pneumoniae; MDR, multidrug-resistant; P. aeruginosa, Pseudomonas aeruginosa. most common isolates in both transplant procedures. In auto-HSCT, the rates of ceph-NS and carba-NS isolates in E. coli and K. pneumoniae and the MDR rate in P. aeruginosa were similar to those reported in the general Italian hospitalized population [14] . Conversely, in allo-HSCT recipients the rates of resistance were significantly higher; ceph-NS isolates accounted for about 40% of E. coli and 78% of K. pneumoniae isolates and carba-NS isolates for 57% of K. pneumoniae, and MDR was detected in about 38% of P. aeruginosa isolates. The hospitalizations and exposition to multiple antibiotics courses during the pretransplant period presumably justify the greater selection of microorganisms with reduced susceptibility phenotypes in allo-HSCT.
We found that diagnosis of acute leukemia, a transplant from an HLA-mismatched donor (related or unrelated) and cord blood, older recipient age, and prolonged neutropenia were independent risk factors of for-engraftment GNB in allo-HSCT. Conversely, ex vivo T-cell depletion was protective, presumably related to the earlier engraftment and lower rate of early posttransplant complications (ie, GVHD), which characterize certain graft manipulations [26] . In the setting of auto-HSCT, a diagnosis of lymphoma, older age, and no antibacterial prophylaxis were predictive of GNB. It is of interest that fluoroquinolone prophylaxis had different effects in the 2 transplant populations; it halved the rate of GNB after auto-HSCT but had no impact in allo-HSCT. Whether antibacterial prophylaxis is still indicated in neutropenic patients in an era of antibiotic resistance is a debated issue, and some centers no longer administer it given the high rate of fluoroquinolone resistance and the possible negative impact of prophylaxis in the selection of resistant intestinal flora [27] [28] [29] . Our data suggest that in high-risk patients with a history of antimicrobial pressure, like those undergoing allo-HSCT, fluoroquinolone prophylaxis is no longer protective, at least against GNB. However, low-risk patients not receiving antibiotic treatment-for example, patients with multiple myeloma who receive auto-HSCT immediately after nonintensive remission induction therapystill seem to benefit from selective intestinal decontamination with fluoroquinolones during neutropenia. Our data are in agreement with those reported earlier in neutropenic patients with multiple myeloma undergoing auto-HSCT [30] .
Pretransplant infection in allo-HSCT and colonization by resistant gram-negative bacteria in both allo-and auto-HSCT were highly predictive of a pre-engraftment infection by a pathogen with the same susceptibility phenotype [6] . Absent molecular characterization of the isolates, we could not demonstrate whether the same pathogen was responsible for both the pretransplant infection or colonization and the posttransplant GNB; however, this correlation seems highly reliable in the majority of cases. Indeed, the high rate of early infection relapses observed in allo-HSCT recipients with a pretransplant infection by a resistant pathogen may suggest the failure of previous antibiotic treatment to eradicate the infection, particularly by carba-NS pathogens. The predictive role of pretransplant infection and colonization in certain MDR infections may have relevance in the definition of the infection-control strategies and the selection of patients or conditions deserving tailored front-line treatments with old and new antibiotics [5, 8, 9, 31, 32] .
Overall, the mortality rate 4 months after transplant was 13.7% for allo-HSCT and 3% for auto-HSCT. In addition to the wellknown factors predicting poor outcome (in allo-HSCT: acute leukemia, previous auto-HSCT, disease not in complete remission at the time of transplant, older recipient age, prolonged pre-engraftment neutropenia, acute GVHD; in auto-HSCT: a lymphoma diagnosis, prolonged neutropenia during the month before transplant, disease not in complete remission at the time of transplant, and prolonged pre-engraftment neutropenia), GNB represented an independent prognostic factor in both populations and GNB was the cause of death in 39.1% of allo-HSCT recipients and 36.4% of auto-HSCT recipients who died before engraftment. The poor prognostic impact of GNB was related mainly to infections by carba-NS enterobacteria and by P. aeruginosa, regardless of the susceptibility pattern, whereas the outcome in patients infected by carba-S enterobacteria did not differ significantly from that in patients who did not experience any GNB [33] . This finding further underlines the importance of early tailored treatment strategies in patients at risk of infections by MDR pathogens [5, 6, 8, 9] .
In conclusion, our study identifies incidence and risk factors for pre-engraftment GNB in a real-life HSCT scenario. It confirms that the phenomenon of antimicrobial resistance is relevant, particularly in allo-HSCT recipients, and dramatically affects overall outcome. Previous infectious history and colonization monitoring represent major indicators of the GNB risk. The results of the present study may be useful to identify HSCT subpopulations who might benefit from targeted antibiotic treatments, and they underline the crucial importance of continuous epidemiological monitoring in defining appropriate infection-control strategies. Figure 4 . Probability of survival 4 months after allogeneic hematopoietic stem cell transplantation (allo-HSCT) according to the development of pre-engraftment gram-negative bacteremia caused by different species. (The probability of survival was not calculated for other pathogens, for which the number of episodes was very low.) Abbreviations: Carba-NS, nonsensitive to carbapenems; carba-S, sensitive to carbapenems; ceph-NS, nonsensitive to the third-generation cephalosporin ceftazidime; ceph-S, sensitive to ceftazidime; E. coli, Escherichia coli; K. pneumoniae, Klebsiella pneumoniae; MDR, multidrug-resistant; P. aeruginosa, Pseudomonas aeruginosa.
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